TW200626133A - Oral medication for twice-daily administration - Google Patents

Oral medication for twice-daily administration

Info

Publication number
TW200626133A
TW200626133A TW094147075A TW94147075A TW200626133A TW 200626133 A TW200626133 A TW 200626133A TW 094147075 A TW094147075 A TW 094147075A TW 94147075 A TW94147075 A TW 94147075A TW 200626133 A TW200626133 A TW 200626133A
Authority
TW
Taiwan
Prior art keywords
twice
daily administration
oral medication
cysteine
salt
Prior art date
Application number
TW094147075A
Other languages
Chinese (zh)
Other versions
TWI405569B (en
Inventor
Minoru Okada
Yoichi Onuki
Toshiaki Kurazumi
Hiroshi Otaki
Original Assignee
Ssp Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ssp Co Ltd filed Critical Ssp Co Ltd
Publication of TW200626133A publication Critical patent/TW200626133A/en
Application granted granted Critical
Publication of TWI405569B publication Critical patent/TWI405569B/en

Links

Abstract

The invention provides an oral medication for twice-daily administration, which includes L-cysteine and ascorbic acid resistant preparation for pigmentation treatments of seborrheic keratosis, freckles, suntan, and macula. The twice-daily administration contains L-cysteine or salt thereof and ascorbic acid resistant or salt thereof, in which once dosage of L-cysteine is 90 mg to 150 mg.
TW094147075A 2005-01-21 2005-12-28 Oral formulation for the treatment of pigmentation symptoms in twice-daily administration TWI405569B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005014103A JP5576006B2 (en) 2005-01-21 2005-01-21 Oral dosage form twice a day

Publications (2)

Publication Number Publication Date
TW200626133A true TW200626133A (en) 2006-08-01
TWI405569B TWI405569B (en) 2013-08-21

Family

ID=36957958

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094147075A TWI405569B (en) 2005-01-21 2005-12-28 Oral formulation for the treatment of pigmentation symptoms in twice-daily administration

Country Status (5)

Country Link
JP (1) JP5576006B2 (en)
KR (1) KR20060085173A (en)
CN (1) CN1839826B (en)
HK (1) HK1092734A1 (en)
TW (1) TWI405569B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5733930B2 (en) * 2009-09-09 2015-06-10 武田薬品工業株式会社 Solid preparation
KR101237498B1 (en) * 2010-10-20 2013-02-26 주식회사 동구제약 Pharmaceutical composition containing ascorbic acid and tranexamic acid having enhanced stability
CN108451914A (en) * 2018-05-31 2018-08-28 南京中生生物科技有限公司 A kind of vitamin C oral disintegration tablet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004026786A (en) * 2002-05-10 2004-01-29 Takeda Chem Ind Ltd Vitamin preparation
DE60332163D1 (en) * 2002-12-27 2010-05-27 Daiichi Sankyo Healthcare Co COMPOSITION FOR SKIN TREATMENT

Also Published As

Publication number Publication date
CN1839826B (en) 2012-11-07
HK1092734A1 (en) 2007-02-16
TWI405569B (en) 2013-08-21
JP2006199640A (en) 2006-08-03
JP5576006B2 (en) 2014-08-20
CN1839826A (en) 2006-10-04
KR20060085173A (en) 2006-07-26

Similar Documents

Publication Publication Date Title
NL300889I2 (en) Trifluridine in combination with tipiracil hydrochloride
EA201492010A1 (en) APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS
NZ604662A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
WO2007056264A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
NZ605841A (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
PT2210605T (en) Once daily dosage forms of trospium
TNSN07419A1 (en) Methods for treating drug resistant cancer
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
NO20080244L (en) Dosage control for prasugrel
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
AR061233A1 (en) FORMULATION OF PROLONGED LIBERATION OF NALTREXONA
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
TW200626133A (en) Oral medication for twice-daily administration
IL173822A0 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
SE0000698D0 (en) Use of a composition
NZ602032A (en) Oral b12 therapy
MX2010006310A (en) O-desmethyl-venlafaxine for treating major depressive disorder.
DK2091520T3 (en) ORAL DOSAGE FORM CONTAINING TRISUBSTITUTED GLYCEROL COMPOUNDS
WO2007144889A3 (en) Treatment of neurofibromatosis
TW200633722A (en) Complexes made using low solubility drugs
NZ726636A (en) Novel compounds and compositions for targeting cancer stem cells
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep